Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype.

OBJECTIVES To compare three methods for using HIV-1 genotype to predict antiretroviral drug susceptibility. METHODS We applied three genotypic interpretation algorithms to 478 reverse transcriptase (RT) and 410 protease sequences for which phenotypic data were available. Sequences were obtained from clinical practice and from published sequences in the Stanford HIV-1 RT and Protease Sequence Database. The genotypic interpretation algorithms included: Stanford HIVdb program (HIVdb), the Visible Genetics/Bayer Diagnostics Guidelines 6.0 (VGI) and a genotypic interpretation program (AntiRetroScan, ARS) developed at the University of Siena, Italy. Genotypic interpretations were normalized to a three-level output: susceptible, intermediate and resistant. Discordances were defined as differences between genotype and phenotype for the same virus isolate. Discordances for which an isolate was considered susceptible by one test but resistant by another test were considered major discordances. RESULTS The frequency of major discordances between genotype and phenotype was 10.6, 13.7 and 15.7% for ARS, VGI and HIVdb, respectively (P < 0.0001 for ARS versus HIVdb and for ARS versus VGI; P = 0.002 for VGI versus HIVdb). The correlation between genotype and phenotype was highest for non-nucleoside RT inhibitors and lowest for nucleoside RT inhibitors. Half of the major discordances involved stavudine, didanosine and zalcitabine. The concordance among the three genotypic algorithms was high, with weighted Kappa values ranging between 0.76 and 0.84 for the pairwise comparisons between each of the algorithms. CONCLUSIONS Genotype interpretation algorithms correctly predict phenotype in 85-90% of cases, but the rate of concordance is not uniformly distributed among different drugs. These data provide insight into the potential additional benefit derived from phenotyping.

[1]  F. Heinz,et al.  Comparison of virtual phenotype and HIV‐SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains , 2002, HIV medicine.

[2]  V. Calvez,et al.  Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial , 2001, Antiviral therapy.

[3]  B. Schmidt,et al.  Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy. , 2002, AIDS reviews.

[4]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[5]  John Rockfeller McCormick Memorial Fund Journal of infectious diseases , 1997 .

[6]  J. Montaner,et al.  Discrepant results in the interpretation of HIV‐1 drug‐resistance genotypic data among widely used algorithms , 2003, HIV medicine.

[7]  R. Haubrich,et al.  Phenotypic and Genotypic Resistance Assays: Methodology, Reliability, and Interpretations , 2001, Journal of acquired immune deficiency syndromes.

[8]  S. Hammer,et al.  Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine , 2000, AIDS.

[9]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[10]  D. Kuritzkes,et al.  Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. , 2001, The Journal of infectious diseases.

[11]  D. Kempf,et al.  Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy , 2001, Antiviral therapy.

[12]  Bradley J. Betts,et al.  Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database , 2000, Nucleic Acids Res..

[13]  Brendan Larder,et al.  A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.

[14]  H. Fleury,et al.  Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. , 1999, AIDS.

[15]  D. Katzenstein,et al.  Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. , 2002, Journal of acquired immune deficiency syndromes.

[16]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[17]  C. Tinelli,et al.  Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. , 2003, Journal of acquired immune deficiency syndromes.